CEBPA and head and neck cancer: These findings suggest that the binding of phosphorylated C/EBPa to the lncRNA UCA1 promoter and lncRNA UCA1 expression is CD44/PI3/AKT-dependent and GDC-0941/GSK795-sensitive in HA-treated CD44v3high head and neck cancer cells.